Founded in 2018, Antios Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases
Our lead therapeutic candidate, ATI-2173, is a first-in-class Active Site Polymerase Inhibitor Nucleotide (ASPIN) that is in clinical development as the backbone of an oral, once-daily potentially curative treatment for HBV. To-date, we have completed extensive pre-clinical work, as well as Phase 1 studies in both healthy volunteers and HBV-infected individuals. A Phase 2a study of ATI-2173 in HBV-infected and HBV/Hepatitis delta virus (HDV) co-infected individuals is currently underway.